Boehringer Ingelheim

This study tested whether a medicine called spesolimab helps adults with moderate to severe hidradenitis suppurativa, a chronic skin condition that causes painful lumps and boils. Participants were randomly assigned to receive either spesolimab or a placebo (dummy treatment) as i…

This study tested whether a new oral medication called BI 685509 could help control progressive systemic sclerosis, also known as scleroderma. Over 200 adults with active disease took either the drug or a placebo pill three times daily for at least 11 months. Researchers measured…

This study monitored the safety and effectiveness of Jardiance (empagliflozin) in Korean patients with chronic kidney disease during routine medical care. Researchers tracked side effects and measured kidney health markers in 299 patients over 24 weeks. The goal was to understand…

This study tested whether a drug called spesolimab helps adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps and tunnels under the skin. Over 200 participants received either spesolimab injections or a placebo (dummy tr…

This study tested whether a new intravenous drug called BI 655130 could safely reduce symptoms of palmoplantar pustulosis (PPP), a painful condition causing blisters and scaling on the palms and soles. In this 16-week trial, 59 adults with PPP received either the drug or a placeb…

This study tested whether a single intravenous dose of an experimental drug called spesolimab could quickly treat severe, sudden flares of generalized pustular psoriasis (GPP). It compared spesolimab to a placebo in 53 adult patients experiencing a moderate-to-severe flare. The m…

This early-stage study tested two new immunotherapy drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the highest safe dose of these drugs, either alone or in combination, that pati…

This early-stage trial tested a new drug called BI 754091 (ezabenlimab) in 110 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest and most effective dose by carefully monitoring side effects. Researchers also…

This study followed adults with hidradenitis suppurativa (HS) for about two years to see if a medicine called spesolimab is safe and effective for long-term use. Participants received injections every two weeks, and doctors tracked their skin symptoms and any side effects. The go…

This early-stage study tested a new cancer pill called brigimadlin in adults with advanced solid tumors that had spread or couldn't be treated with standard options. Researchers aimed to find the highest safe dose patients could tolerate, then used that dose to see if the medicat…

This study tested whether a drug called spesolimab could help control moderate-to-severe ulcerative colitis in patients who hadn't responded well to other biologic treatments. About 98 adults received either the drug or a placebo for 12 weeks to see if it could reduce symptoms an…

This study tested a new immunotherapy drug called ezabenlimab, given in combination with other cancer medicines, for adults with advanced cancers that had spread. The goal was to see if these combinations could shrink tumors and control the disease in patients who had already tri…

This early-stage study tested the safety and how the body processes a new oral medication called BI 1015550 in people with idiopathic pulmonary fibrosis (IPF). It involved 15 patients who were not taking other standard IPF medications. The main goal was to see what side effects o…

This study tested whether a weekly injection called survodutide could help adults with obesity and a serious fatty liver disease called NASH. Over 200 participants were randomly assigned to receive either the real medicine or a placebo (dummy injection) for 48 weeks, alongside di…

This large, completed Phase 3 trial tested whether a new oral medicine called BI 1015550 could help adults with progressive fibrosing interstitial lung diseases (PF-ILDs). Over 1,100 participants were randomly assigned to take either one of two doses of the medicine or a placebo …

This study tested whether an oral medicine called BI 907828 could help control advanced cancers of the bile duct, pancreas, lung, or bladder that had a specific genetic pattern (MDM2 amplified, TP53 wild-type) and had stopped responding to standard treatments. All 99 participants…

This early-stage study tested the safety of a new weekly injectable drug, BI 3006337, in adults who have both overweight/obesity and fatty liver disease. The main goal was to find the highest dose participants could tolerate without serious side effects. Researchers also checked …

This small study tested a new drug called BI 655130 in 8 people with active ulcerative colitis. The main goal was to understand how the drug works in the gut and to check if it was safe. Researchers measured changes in gut tissue and inflammation markers over 12 weeks of treatmen…

This completed Phase 3 trial tested whether a new oral medication called brigimadlin helps control advanced dedifferentiated liposarcoma, a rare and aggressive cancer of fat tissue. The study involved 138 adults with this cancer who took brigimadlin tablets once every three weeks…

This study tested whether a weekly injectable medication called survodutide helps people with obesity lose weight. About 274 Japanese adults with obesity and related health problems like type 2 diabetes or high blood pressure participated. For 76 weeks, two-thirds received survod…

This study tested an experimental injectable drug called BI 655130 to see if it could reduce painful, pus-filled blisters on the palms and soles in people with a skin condition called palmoplantar pustulosis (PPP). 152 adults with moderate to severe PPP received either one of fou…

This study tested whether a medicine called spesolimab could help adults with Crohn's disease who have painful fistulas near the anus. Twenty-seven participants were randomly assigned to receive either the drug or a placebo via an IV drip every four weeks for 24 weeks. Doctors tr…

This study tested whether a new oral medicine called BI 764198 could help control a serious kidney disease called focal segmental glomerulosclerosis (FSGS). For about 3 months, 67 adult participants took either one of three different doses of the medicine or a placebo pill. Resea…

This early-stage study tested a combination of two immunotherapy drugs (BI 754111 and BI 754091) in adults with advanced solid tumors, including non-small cell lung cancer. The first goal was to find the safest highest dose. The second goal was to see if this combination could sh…

This study tested whether a new weight-loss medicine called survodutide (BI 456906) is safe for the heart. It involved 110 otherwise healthy adults with overweight or obesity who received weekly injections for about 30 weeks. Researchers closely monitored participants' heart rhyt…

This study tested whether a weekly injection called survodutide helps adults in China with overweight or obesity lose weight. Over 300 participants were randomly assigned to receive one of two doses of the drug or a placebo injection for about 19 months. Researchers measured chan…

This was a first-in-human study to find a safe and tolerable dose of a new oral drug, BI 3706674, for adults with advanced stomach or esophageal cancer that had stopped responding to other treatments. The trial tested different dose levels to see how the drug was processed by the…

This program provided early access to an intravenous drug called spesolimab for adults in China suffering from severe, sudden flare-ups of Generalized Pustular Psoriasis (GPP), a rare and serious skin disease. It was for patients who had no other satisfactory treatment options av…

This study tested a new medicine called BI 1291583 for adults with cystic fibrosis who also have a lung condition called bronchiectasis. For 12 weeks, participants took either the new tablet or a placebo (dummy pill) to see how safe it was and if it could reduce a harmful enzyme …

This early-stage study tested a new combination of two drugs, BI 836880 and ezabenlimab, in adults with advanced non-small cell lung cancer and other solid tumors. The first part aimed to find the safest dose. The second part then used that dose to see if the treatment could shri…

This early-phase study tested two new drugs, BI 754091 and BI 754111, in Asian patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest and most effective doses of the drugs, both alone and in combination, and …

This study tested an experimental drug called BI 770371 in people with advanced liver scarring (cirrhosis) caused by MASH, a serious fatty liver disease. Twenty-eight participants were randomly assigned to receive either the drug or a placebo via IV infusion every three weeks for…

This large, completed Phase 3 trial tested whether a new oral medicine called BI 1015550 could help adults with Idiopathic Pulmonary Fibrosis (IPF), a serious lung-scarring disease. Over 1,100 participants, some already on standard IPF drugs, were randomly assigned to take either…

This was the first study in humans to test a new cancer drug called BI 836880. It involved 29 patients with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the highest safe dose of the drug and understand how the body handles it…

This was an early safety study to test a new cancer drug called BI 836880 in people with advanced solid tumors. The main goal was to find the highest dose patients could tolerate without severe side effects. Researchers gave the drug weekly to 24 patients and closely monitored th…

This study tested whether a daily pill called afatinib works better than a standard intravenous chemotherapy (methotrexate) for patients with advanced head and neck cancer that has continued to grow after initial platinum-based treatment. It involved 340 patients and aimed to see…

This study tested whether adding a new injectable drug called BI 655064 to standard treatment could better control kidney damage in people with active lupus nephritis. 121 adults with this serious kidney complication received either one of three drug doses or a placebo injection …

This study tested the long-term safety of nintedanib, a medication that slows lung scarring, in children and adolescents with progressive interstitial lung disease. Participants aged 6-17 took nintedanib capsules twice daily for at least 3 years while researchers monitored for si…

This study tested whether a new oral medication called brigimadlin could work better than standard chemotherapy (doxorubicin) for people with advanced dedifferentiated liposarcoma, a rare and aggressive cancer. 400 adults who hadn't received prior treatment for this cancer were r…

This study tested whether a new oral medicine called BI 1819479 could help slow the progression of idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. Over 300 adults with IPF took either one of three different doses of the medicine or a placebo pill for 6 to 12…

This study tested whether a weekly injectable medication called survodutide helps adults with overweight or obesity lose weight. Over 700 participants, who had previously struggled to lose weight through diet alone, received either the drug or a placebo for about a year and a hal…

This study tested the safety and effectiveness of adding a new investigational drug, BI 655130, to standard therapy for adults with mild-to-moderate ulcerative colitis. The goal was to see if the add-on treatment could improve healing of the intestinal lining in patients whose di…

This study tested a combination of two cancer drugs, brigimadlin and ezabenlimab, in adults with advanced solid tumors that had stopped responding to standard treatments. The first part aimed to find the highest safe dose of the drug combination. The second part aimed to see if t…

This study followed 79 adults with moderate to severe ulcerative colitis who had already participated in earlier trials of the drug spesolimab. Its main goal was to check the long-term safety of continuing this treatment. Researchers also looked at whether patients maintained sym…

This study tested an investigational drug called BI 655130, given by IV infusion, to see if it is safe and effective for adults with moderate to severe atopic dermatitis (eczema). It compared the drug to a placebo in 51 patients over 16 weeks. The main goal was to see how much th…

This study aimed to create and test a screening tool to help doctors decide which rheumatoid arthritis patients should get a special lung scan. It involved over 1,300 patients who had arthritis and were at higher risk for a serious lung complication. Researchers checked if a mode…

This study tested whether a medicine called spesolimab, given as a monthly injection, could prevent painful and serious skin flare-ups in people with a history of generalized pustular psoriasis (GPP). About 123 adolescents and adults whose skin was currently clear received either…

This study tested whether a medicine called iclepertin could improve thinking, learning, and memory in people with schizophrenia. About 620 adults with stable schizophrenia took either iclepertin or a placebo pill daily for 26 weeks, while continuing their regular medications. Do…

This study tested whether a daily pill called iclepertin could improve learning, memory, and thinking skills in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo (a dummy pill) for 26 weeks while continuing their standard schizophrenia medicatio…

This study tested whether the medication atomoxetine could help reduce impulsive behavior in adults with ADHD. Over 14 days, 63 participants either received the drug or a placebo and completed questionnaires about their impulsivity. The main goal was to see if the drug led to mea…

This study tested whether a medicine called Iclepertin could help improve common thinking and memory problems in people with schizophrenia, like trouble remembering things or paying attention. Over 600 adults with stable schizophrenia took either Iclepertin or a placebo pill dail…

This early-stage study aimed to check the safety and how the body processes a new compound called BI 3810477. It involved 47 healthy adult volunteers who received either the compound or a placebo. The main goal was to see what side effects might occur and to measure how much of t…

This early-stage study aimed to understand how eating food affects the way the body absorbs an experimental drug called BI 1015550. It involved 12 healthy male volunteers who took the drug both with and without food. The main goal was to measure drug levels in the blood to see if…

This early-stage study aimed to understand how the body absorbs, processes, and eliminates an experimental cancer drug called BI 1810631 (zongertinib). Researchers gave the drug to 15 healthy male volunteers in two different forms—as a liquid and as a pill—and tracked how much of…

This early-stage study aimed to understand how taking carbamazepine, a common medication, affects how the body processes a single dose of an experimental drug called BI 1810631. It involved 16 healthy male volunteers who took both drugs in a specific sequence. The goal was to gat…

This study aimed to see if a new version of a drug pill (Formulation C2) gets into the bloodstream the same way as an older version (Formulation C1). It involved 64 healthy adults who each took a single dose of both pill types at different times. The goal was to confirm the two v…

This study monitored patients in Japan who were newly prescribed the intravenous drug spesolimab for severe flare-ups of generalized pustular psoriasis (GPP). The main goal was to track any side effects that occurred in a real-world setting, outside of a controlled clinical trial…

This study tested how the body absorbs two different pill versions of an experimental drug called BI 1810631. Researchers also checked if eating food or taking a common heartburn medication changes how the drug works. The study involved 13 healthy male volunteers to gather this b…

This was an early-stage study to check the safety and see how the body processes a new drug called BI 3006337. It involved 80 healthy male volunteers who received a single injection. The main goal was to find out what side effects might occur and to measure how much of the drug g…

This early-stage study tested how the body absorbs two different pill versions of an experimental drug called nerandomilast. It involved 15 healthy adults to see if one version works better than the other and whether taking the pill with food changes how much drug gets into the b…

This early-stage study tested how eating food affects the body's absorption of an experimental cancer drug called BI 1810631 (Zongertinib). Sixteen healthy men took a single dose of the drug once after fasting and once after a meal. The goal was to see if food changes how much of…

This early-stage study aimed to understand how taking multiple doses of a new drug, BI 1015550, affects how the body processes a common sedative called midazolam. It involved 15 healthy male volunteers who took both drugs in a specific sequence. The goal was to gather safety data…

This early-stage study aimed to understand how a new drug, BI 655130, is absorbed and processed by the body. It involved 36 healthy volunteers to compare how the drug behaves when given as an injection under the skin versus directly into a vein. The main goal was to check the dru…

This early-stage study aimed to understand how a new drug called BI 425809 moves through the body and into the brain's spinal fluid. It involved 25 healthy male volunteers who took different oral doses. Researchers measured drug levels in blood and spinal fluid over time to check…

This early-stage study aimed to understand how an experimental drug called BI 425809 affects how the body processes a common sedative called midazolam. The study involved 15 healthy male volunteers who received both drugs. Researchers measured drug levels in the blood to see if B…

This early-stage study aimed to check the safety and see how the body processes a new oral drug called BI 3009947. It involved 40 healthy male volunteers. Researchers tested different doses and pill formulations to see how much of the drug gets into the bloodstream and if taking …

This early-stage study tested how a common antifungal medication (itraconazole) affects blood levels of an experimental cancer drug called BI 1810631. Researchers gave both drugs to 16 healthy male volunteers to measure potential interactions. The goal was to understand safety in…

This study aimed to check if a new version of an experimental drug (BI 1015550) gets into the bloodstream the same way as the original version. It involved 64 healthy adults who each took both versions at different times. The goal was to confirm the two pill formulas are essentia…

This early-stage study aimed to understand how the body processes, breaks down, and eliminates an experimental drug called BI 1015550. Six healthy male volunteers took a single, specially labeled dose so researchers could track it. The main goal was to measure how much of the dru…

This study tested if a new version of the drug zongertinib, made by a different manufacturer, works the same way in the body as the original version. It involved 56 healthy adults who each took both versions. Researchers measured drug levels in the blood to see if they were equiv…

This study aimed to understand how a new drug, BI 1584862, is absorbed, processed, and eliminated by the body. Eight healthy men received a single dose of the drug, which was specially tagged to allow tracking. Researchers measured how much of the drug and its breakdown products …

This study tested how a new medicine for obesity and liver disease behaves in people with different levels of kidney function. Researchers gave a single injection to 42 adults, comparing those with healthy kidneys to those with mild, moderate, or severe kidney problems. The goal …

This study aimed to understand how a common antifungal drug (itraconazole) affects the levels of an experimental drug (BI 3031185) in the body. It involved 14 healthy male volunteers who took both drugs. The goal was to gather basic safety and interaction data to inform future re…

This early-stage study aimed to understand how taking one drug (bosentan) might change how the body processes another drug (nerandomilast). It involved 16 healthy male volunteers who took both drugs in a specific sequence. The main goal was to measure the levels of nerandomilast …

This early-stage study aimed to understand how a common antifungal drug (itraconazole) affects the way the body processes a new experimental medication (BI 1015550). It involved 16 healthy male volunteers who received the drugs alone and together. The main goal was to measure dru…

This small, early-stage study tested how the body absorbs the diabetes medication empagliflozin when taken in different ways. Fourteen healthy volunteers took the drug either as a whole tablet or dissolved in water and mixed with food. The goal was to see if these different metho…

This study aimed to understand how liver cirrhosis affects the way the body processes common medicines. Researchers compared healthy adults to adults with mild or moderate liver cirrhosis. All participants took a single, safe dose of five different approved medicines, and doctors…

This early-stage study aimed to understand how the body absorbs, breaks down, and eliminates a single dose of an experimental drug called BI 1291583. Eight healthy male volunteers received a specially labeled version of the drug. Researchers then carefully measured how much of it…

This was an early-stage study to check the safety and see how the body processes a new drug called BI 3006337. It involved 36 healthy Japanese men who received injections of the drug or a placebo over several weeks. The main goal was to understand the drug's side effects and how …

This study aimed to monitor the safety of the drug Ofev in real-world patients in Japan with a specific type of progressive, scarring lung disease. It tracked 425 patients who were newly prescribed Ofev to see what side effects, especially liver problems, they experienced. The go…

This study aimed to understand if taking a new experimental drug, BI 1015550, with or without food changes how the body absorbs it. It involved 18 healthy volunteers who took a single dose under different conditions. The goal was to gather basic information to help plan how the d…

This study aimed to understand if a new injectable drug for weight management (BI 456906/Survodutide) changes how the body processes three common substances: caffeine, a sleep aid (midazolam), and an antidepressant (bupropion). It involved 34 otherwise healthy adults with overwei…

This was the first-ever study in humans of a new drug called BI 3034701. Its main goal was to check the safety and side effects of different doses in healthy men and in people who are overweight or obese. Researchers also measured how the drug moved through the body after being g…

This small, early-stage study aimed to understand how much of an experimental drug called BI 1015550 gets into the bloodstream when taken as a pill compared to when it's given directly into a vein. It involved 8 healthy male volunteers to gather basic data on how the body process…

This early-stage study aimed to understand how a new drug called BI 1015550 moves through the body and how safe it is. It involved 24 healthy Chinese men and women who received a single dose. The main goal was to gather basic safety data and see how the drug is processed, not to …

This early-stage study tested two experimental cancer drugs—BI 836880 alone and combined with BI 754091—in 21 Japanese patients with advanced solid tumors. The main goal was to find the highest safe doses for future research, not to treat cancer. Researchers carefully monitored h…

This early-stage study aimed to compare how two different versions of the same experimental drug, BI 456906, are absorbed into the bloodstream. It involved 16 healthy adults to see if a new formulation works similarly to the original one. The goal was to gather basic data on how …

This early study tested a new cancer drug called BI 907828 in adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to see if taking common medications (an antibiotic or an antifungal) at the same time changed how much of the canc…

This study tested whether a new drug called BI 1015550 affects the heart's electrical rhythm in healthy people. Forty-six healthy volunteers received different single doses of the drug, a placebo, and a comparison drug to see if it caused any concerning changes. The main goal was…

This early-stage study aimed to understand how the body absorbs two different combinations of the drugs vicadrostat and empagliflozin. It also tested whether taking the drugs with food changes how they work in the body. The study involved 32 healthy adult volunteers who each rece…

This study tested how a medicine called BI 1015550 behaves in people with and without liver problems. Researchers compared 28 adults with mild or moderate liver impairment to matched healthy participants, giving everyone a single dose. They measured drug levels in the blood over …

This study aimed to understand how carbamazepine, a drug used for conditions like seizures, affects how the body processes a new drug called nerandomilast. It involved 16 healthy male volunteers who took both drugs in a specific order. The goal was to gather safety data for futur…

This study aimed to compare how three different formulations (recipes) of an investigational drug called BI 456906 are absorbed into the bloodstream. It involved 30 healthy adult volunteers who each received a single dose of each formulation. The main goal was to see if the new f…

This was an early-stage study to check the safety and see how the body processes a new drug called BI 1015550. It involved 42 healthy male volunteers. Researchers gave participants single and then multiple doses to monitor for side effects and measure how long the drug stayed in …

This was a very early, small study to check if a new drug called BI 1015550 is safe for people and to see how the body processes it. It involved 16 healthy Japanese men who took a single dose of the drug or a placebo. The main goal was to watch for any side effects and measure th…

This early-stage study aimed to understand how the body absorbs a new experimental drug, BI 1015550, when given as different pill versions. It involved 24 healthy volunteers to compare the planned commercial pill formula with an earlier test version and to see if taking the pill …

This study aimed to see if a new drug candidate, BI 3000202, changes how the body processes two common medications: rosuvastatin (a cholesterol drug) and digoxin (a heart drug). It involved 14 healthy adults who took the two common drugs together, then took them again along with …

This early-stage study tested whether an experimental cancer drug called zongertinib changes how the body processes other common medications. Researchers gave 32 healthy men zongertinib along with drugs like a blood thinner (dabigatran), a cholesterol pill (rosuvastatin), a diabe…

This study aimed to understand how taking an existing medication for heart and lung conditions (bosentan) might change the way the body processes an experimental drug (BI 425809). It involved 14 healthy male volunteers who took the drugs in a specific sequence. The goal was to me…

This early-stage study aimed to understand how the body absorbs an experimental drug called BI 655130 when it is injected under the skin in different ways and locations. It involved 48 healthy adult volunteers to compare injections in the belly button area versus the thigh, and s…

This study aimed to understand how liver cirrhosis affects how the body processes medicines. Researchers compared healthy adults to adults with liver cirrhosis by giving them single doses of four common drugs (rosuvastatin, digoxin, metformin, and furosemide) and measuring drug l…

This early-stage study aimed to understand how a new cancer drug called zongertinib might affect the way the body processes three other common medications: a sedative, a heartburn drug, and a diabetes medication. It involved 16 healthy male volunteers who took the other drugs alo…

This early-stage study aimed to understand how a new drug, BI 1015550, is absorbed and processed by the body. It involved 12 healthy Japanese male volunteers who received a single oral dose. The main goal was to measure the drug's levels in the blood over time to see how the body…

This study aimed to see if taking a new drug candidate (BI 1015550) changes how the body processes two existing medications for lung scarring (nintedanib and pirfenidone). It involved 14 healthy male volunteers. Researchers measured drug levels in the blood to check for safe inte…

This study aimed to understand how kidney problems affect how the body processes an experimental medicine called BI 1015550. It involved 26 adults, some with healthy kidneys and some with moderate or severe kidney impairment. Each participant took a single dose, and researchers m…

This was a first-in-human study to check the safety and see how the body processes a new drug called BI 706321. It involved 73 healthy male volunteers who received either the drug or a placebo. The main goals were to see if the drug was safe at different doses and to measure how …

This early-stage study tested how a common antibiotic (erythromycin) affects the levels of an experimental drug (BI 1291583) in the body. It involved 20 healthy adults to see if taking both drugs together changes how the experimental drug is processed. The goal was to gather basi…

This study aimed to understand if changes in a standard lung function test (FVC) over one year of treatment with the drug nintedanib are related to changes in patients' reported cough and shortness of breath. It observed 158 adults with progressive, scarring lung diseases (exclud…

This early-stage study aimed to understand how the body processes an experimental drug called BI 706321 when taken with a common antifungal medication, itraconazole. It involved 14 healthy male volunteers who took the drugs in a specific sequence. The goal was to measure drug lev…